Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| ciliated cell | 18 studies | 43% ± 20% | |
| epithelial cell | 5 studies | 37% ± 11% | |
| deuterosomal cell | 4 studies | 28% ± 6% | |
| transit amplifying cell | 4 studies | 23% ± 4% | |
| enterocyte | 4 studies | 18% ± 2% | |
| type I pneumocyte | 4 studies | 27% ± 9% | |
| abnormal cell | 4 studies | 19% ± 3% | |
| basal cell | 3 studies | 28% ± 8% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| lung | 4 studies | 23% ± 4% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| ovary | 100% | 1709.01 | 180 / 180 | 100% | 105.15 | 430 / 430 |
| thymus | 100% | 5625.37 | 653 / 653 | 100% | 149.37 | 605 / 605 |
| uterus | 100% | 2268.88 | 170 / 170 | 100% | 190.46 | 458 / 459 |
| prostate | 100% | 3015.97 | 245 / 245 | 99% | 79.62 | 498 / 502 |
| pancreas | 100% | 1845.40 | 328 / 328 | 99% | 97.59 | 176 / 178 |
| intestine | 100% | 2214.66 | 966 / 966 | 99% | 128.27 | 520 / 527 |
| esophagus | 100% | 2134.92 | 1440 / 1445 | 99% | 76.98 | 181 / 183 |
| stomach | 100% | 1858.11 | 358 / 359 | 99% | 102.45 | 282 / 286 |
| bladder | 100% | 1752.95 | 21 / 21 | 98% | 128.41 | 495 / 504 |
| breast | 100% | 2013.42 | 457 / 459 | 98% | 129.96 | 1099 / 1118 |
| skin | 100% | 2211.21 | 1809 / 1809 | 98% | 82.50 | 461 / 472 |
| lung | 99% | 2450.70 | 575 / 578 | 98% | 88.06 | 1132 / 1155 |
| kidney | 100% | 3999.76 | 89 / 89 | 97% | 84.48 | 878 / 901 |
| adrenal gland | 100% | 4162.49 | 258 / 258 | 96% | 60.17 | 221 / 230 |
| brain | 96% | 1031.50 | 2531 / 2642 | 99% | 70.75 | 698 / 705 |
| liver | 100% | 1832.90 | 226 / 226 | 80% | 52.25 | 324 / 406 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 90.12 | 29 / 29 |
| spleen | 100% | 2238.04 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 168.04 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 212.52 | 1 / 1 |
| blood vessel | 99% | 1431.76 | 1316 / 1335 | 0% | 0 | 0 / 0 |
| heart | 98% | 1715.07 | 845 / 861 | 0% | 0 | 0 / 0 |
| adipose | 98% | 1266.82 | 1179 / 1204 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 90% | 68.29 | 72 / 80 |
| muscle | 58% | 458.94 | 467 / 803 | 0% | 0 | 0 / 0 |
| peripheral blood | 49% | 990.72 | 456 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0060271 | Biological process | cilium assembly |
| GO_0035721 | Biological process | intraciliary retrograde transport |
| GO_0042073 | Biological process | intraciliary transport |
| GO_0005814 | Cellular component | centriole |
| GO_0005930 | Cellular component | axoneme |
| GO_0097542 | Cellular component | ciliary tip |
| GO_0005813 | Cellular component | centrosome |
| GO_0030175 | Cellular component | filopodium |
| GO_0005929 | Cellular component | cilium |
| GO_0097014 | Cellular component | ciliary plasm |
| GO_0036064 | Cellular component | ciliary basal body |
| GO_0005829 | Cellular component | cytosol |
| GO_0005868 | Cellular component | cytoplasmic dynein complex |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0045503 | Molecular function | dynein light chain binding |
| GO_0005515 | Molecular function | protein binding |
| GO_0045504 | Molecular function | dynein heavy chain binding |
| Gene name | DYNC2I2 |
| Protein name | Dynein 2 intermediate chain 2 Cytoplasmic dynein 2 intermediate chain 2 (Dynein 2 intermediate chain 2) (WD repeat-containing protein 34) |
| Synonyms | WDR34 |
| Description | FUNCTION: Acts as one of several non-catalytic accessory components of the cytoplasmic dynein 2 complex (dynein-2 complex), a motor protein complex that drives the movement of cargos along microtubules within cilia and flagella in concert with the intraflagellar transport (IFT) system . DYNC2I2 plays a major role in retrograde ciliary protein trafficking and in ciliogenesis . Required also to maintain a functional transition zone . .; FUNCTION: Acts as a negative regulator of the Toll-like and IL-1R receptor signaling pathways. Inhibits the MAP3K7-induced NF-kappa-B activation pathway. Inhibits MAP3K7 phosphorylation at 'Thr-184' and 'Thr-187' upon Il-1 beta stimulation. . |
| Accessions | ENST00000372715.7 Q96EX3 A2A3F8 ENST00000419989.2 |